Welcome to Lonza Bioscience

PBMC collected from patients were reprogrammed into iPSC by Nucleofection. Generated IPSCs still carry the mutation causing the disease.

High-quality media solutions are vital for recombinant protein manufacture. Discover how Lonza’s new eCHO^TM Medium can support a consistent yield of high-quality products, while being easy and economical to use.

Learn more about our integrated solutions which can support you from drug discovery to development for SARS-CoV-2. Choose from a broad donor panel of airway and immune cells, culture media for primary cells, media and endotoxin testing products for vaccine and protein production, or use our Nucleofector^TM Technology for virus creation.  

The new TheraPEAK^TM SfAAV^TM Medium enhances your AAV production in Sf9 cells and expedites the time to market for safe, scalable and live-saving gene therapies.

Join leading cell therapy thought leaders as they share their insights and lessons learned on advancing therapies from bench to bedside, the challenges they face, and where in their view the fast-evolving cell therapy field is heading.

Presented by CAR-TCR Digital Week

Gain ease of mind by adopting the new GSv9^TM Media and Feeds for protein production, offering high titer and protein quality with low aggregate formation.

As the situation with the COVID-19 pandemic evolves, we will keep you informed about any potential supply disruptions which may occur as a result.

QC Insider^TM Toolbox is packed with comprehensive support tools that will help you perform the bacterial endotoxins test. It has been created by QC experts who face many of the same regulated manufacturing challenges as you do.

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.